Trigeminal neuralgia
Drug research and approvals for trigeminal neuralgia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 23 studies of trigeminal neuralgia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 0 approved and 8 open orphan designations naming it.
- Recruiting worldwide: 23
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot StudyNCT07919444 · Phase 2 · Shaukat Khanum Memorial Cancer Hospital & Research Centre · starts Feb 26, 2025
- RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal NeuralgiaNCT07596485 · Phase 1 / Phase 2 · Kriya Therapeutics, Inc. · starts Sep 10, 2026
- Ultra-Early Gamma Knife Stereotactic Radiosurgery for TNNCT06949436 · Phase 2 · University of Alberta · starts Jul 30, 2025
- Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal NeuralgiaNCT06890897 · Not applicable · Beijing Tiantan Hospital · starts Apr 1, 2025
- Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal NeuralgiaNCT06851910 · Not reported · Hospital Universitari de Bellvitge · starts Apr 21, 2025
- Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal NeuralgiaNCT06779578 · Not applicable · Alexandria University · starts Jan 1, 2024
- Neurosurgical Outcome NetworkNCT06724029 · Not reported · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · starts Dec 5, 2022
- Comparison of Pulsed and Thermal Radiofrequency for Trigeminal NeuralgiaNCT06684275 · Not applicable · Zagazig University · starts Nov 10, 2024
- Emotion and Memory in Chronic Neuropathic PainNCT06518421 · Not reported · University Health Network, Toronto · starts Feb 12, 2024
Approved 1
- CarbamazepineSodium channel alpha subunit blocker
Phase 3 3
- VixotrigineSodium channel protein type IX alpha subunit blocker
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- AmifostineReactive metabolite scavenging agent
Phase 2 7
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- LidocaineSodium channel alpha subunit blocker
- GuanfacineAdrenergic receptor alpha-2 agonist
- RimegepantCalcitonin gene-related peptide type 1 receptor antagonist
- BasimglurantMetabotropic glutamate receptor 5 modulator
- ErenumabCalcitonin gene-related peptide type 1 receptor antagonist
- Carbon dioxide
How its trials ended
112 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 23 whose ending is known, 30% met their primary endpoint, 9% missed it and 61% stopped early.
- Completed, result not reported4338%
- Ongoing3329%
- Status unknown1312%
- Stopped: other or unclear98%
- Met its primary endpoint76%
- Stopped: enrollment or feasibility33%
- Missed its primary endpoint22%
- Stopped: sponsor or business decision22%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Mar 31, 2023 | A phase 1/2, multicenter, open-label study to evaluate the safety, tolerability, and preliminary efficacy of percutaneous injection of RP-008 followed by daily…RP-008 / Varenicline / Prednisone / Prednisolone sodium phosphate | Kriya Therapeutics | Ongoing |
| Nov 3, 2026 | BasimglurantTreatment of trigeminal neuralgia | Noema Pharma AG | Designated |
| May 22, 2026 | Trimeprazine tartrateTreatment of trigeminal neuralgia | Undaunted Bio, Inc. | Designated |
| Jan 31, 2024 | A potent negative allosteric modulator (NAM) of human…Treatment of trigeminal neuralgia | Shanghai SIMR Biotechnology Co., Ltd. | Designated |
| Dec 17, 2015 | Carbon dioxideTreatment of trigeminal neuralgia | Capnia, Inc. | Designated |
| Jul 24, 2013 | VixotrigineTreatment of trigeminal neuralgia | Biogen, Inc. | Designated |
| Mar 16, 2012 | Dehydrated alcoholTreatment of trigeminal neuralgia | Luitpold Pharmaceuticals, Inc. | Designated |
| Jan 6, 1998 | L-baclofenTreatment of trigeminal neuralgia | Osmotica Pharmaceutical Corp. | Designated |
| Jul 13, 1990 | L-baclofenTreatment of trigeminal neuralgia. | Fromm, Gerhard M.D. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA